| Popis: |
Post-liver transplantation Diabetes Mellitus (DM) or PLTDM, affects 30 % of liver transplant patients and is linked to an elevated risk of death & a variety of adverse consequences. PLTDM is a multi-cause disease, however, the use of immunosuppressive drugs from the calcineurin inhibitor (CNI) family is the primary risk factor (tacrolimus and cyclosporine). Other variables, including before-transplant obesity, alcoholic independent steatohepatitis, & hepatitis C virus infection, can enhance the incidence of Post Liver Transplant DM. Only when the dosages of Calcineurin inhibitor & steroids have been stabilized & the stress after the operation has been alleviated should a diagnosis of PLTDM be made. Insulin secretory dysfunction is the most common complication caused by CNI. To enhance long-term success for both the patient and the transplant, plasma glucose management must begin soon after the surgery. Metformin and DPP-4 inhibitors, among the more well-known antidiabetics, have a notably non-malignant profile into the setting of Post Liver Transplant DM & are recommended oral medicines for large duration treatment. Insulin treatment is another viable treatment option for the disorder's underlying pathophysiological problem. There is yet little information on the effects of newer antidiabetic families on Post Liver Transplant DM. With immunosuppressant medicines, the physician managing diabetes, dyslipidemia, and hypertension following transplant must be aware of the increased risk of drug-drug interactions and infections. The increased risk of fluctuating and decreased renal function, which can lead to hypoglycemia, must be included in treatment goals and treatments. While research is underway to develop ways to prevent PTDM, it is critical that immunosuppressive regimes be chosen based on their ability to prolong graft survival rather than to avoid PTDM. |
